Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.51 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28215465 | 0.89 | SMN1; SMN2 (0.53) | SYKKDM4EALDH1A1SMN1; SMN2FFAR1 | |
| SCHEMBL791890 | 0.83 | FFAR1 (0.61) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL15474960 | 0.81 | KDM4E (0.65) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL1073540 | 0.80 | SYK (0.68) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL15474712 | 0.80 | SYK (0.53) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL17712565 | 0.78 | SYK (0.58) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL4852115 | 0.78 | MAOB (0.67) | ABCB1LMNA | |
| SCHEMBL17712563 | 0.77 | SMN1; SMN2 (0.63) | SYKKDM4EALDH1A1SMN1; SMN2FFAR1 | |
| SCHEMBL19089278 | 0.77 | SYK (0.67) | SYKAURKBINCENPABCB1HTR1A | |
| SCHEMBL27557523 | 0.76 | KDM4E (0.50) | SYKAURKBINCENPKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | SYK 663/4885AURKB 165/4885INCENP 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.